Neumora Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
109
- Stock Symbol
-
NMRA
- Investments
-
3
- Share Price
-
$1.19
- (As of Monday Closing)
Neumora General Information
Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Contact Information
Website
www.neumoratx.comCorporate Office
- 490 Arsenal Way
- Suite 200
- Watertown, MA 02472
- United States
Corporate Office
- 490 Arsenal Way
- Suite 200
- Watertown, MA 02472
- United States
Neumora Timeline
Neumora Stock Performance
As of 17-Mar-2025, Neumora’s stock price is $1.19. Its current market cap is $193M with 162M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.19 | $1.28 | $1.16 - $17.19 | $193M | 162M | 3.29M | -$1.53 |
Neumora Financials Summary
As of 31-Dec-2024, Neumora has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,373,985 | 1,373,985 | 2,100,170 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (262,911) | (262,911) | (251,600) | (134,871) |
| Net Income | (243,787) | (243,787) | (235,925) | (130,904) |
| Total Assets | 316,972 | 316,972 | 496,195 | 426,234 |
| Total Debt | 1,853 | 1,853 | 5,231 | 8,442 |
Neumora Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neumora Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Neumora Comparisons
Industry
Financing
Details
Neumora Competitors (2)
One of Neumora’s 2 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA |
Neumora Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neumora Patents
Neumora Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12171758-B1 | Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto | Active | 05-Jul-2023 | ||
| US-11993580-B1 | Methods of treating neurological disorders | Active | 02-Dec-2022 | ||
| US-20240246928-A1 | Methods of treating neurological disorders | Active | 02-Dec-2022 | ||
| US-20240294492-A1 | Methods of treating neurological disorders | Pending | 02-Dec-2022 | ||
| US-20230365534-A1 | Modulators of nlrp3 inflammasome and related products and methods | Pending | 13-May-2022 | C07D401/12 |
Neumora Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neumora Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neumora Acquisitions (3)
Neumora’s most recent deal was a Merger/Acquisition with Blackthorn Therapeutics. The deal was made on 07-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Blackthorn Therapeutics | 07-Oct-2021 | Merger/Acquisition | Drug Discovery | ||
| Alairion | 01-Oct-2021 | Merger/Acquisition | Pharmaceuticals | ||
| Syllable Life Sciences | 08-Aug-2020 | Merger/Acquisition | Other Healthcare Technology Systems |
Neumora ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Neumora FAQs
-
When was Neumora founded?
Neumora was founded in 2019.
-
Where is Neumora headquartered?
Neumora is headquartered in Watertown, MA.
-
What is the size of Neumora?
Neumora has 109 total employees.
-
What industry is Neumora in?
Neumora’s primary industry is Drug Discovery.
-
Is Neumora a private or public company?
Neumora is a Public company.
-
What is Neumora’s stock symbol?
The ticker symbol for Neumora is NMRA.
-
What is the current stock price of Neumora?
As of 17-Mar-2025 the stock price of Neumora is $1.19.
-
What is the current market cap of Neumora?
The current market capitalization of Neumora is $193M.
-
Who are Neumora’s competitors?
NeuroNascent and SAGE Therapeutics are competitors of Neumora.
-
What is Neumora’s annual earnings per share (EPS)?
Neumora’s EPS for 12 months was -$1.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
